In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes

Macromol Biosci. 2010 May 14;10(5):503-12. doi: 10.1002/mabi.200900415.

Abstract

Formulation of docetaxel (DOC), a hydrophobic anticancer drug, was successfully achieved in poly(gamma-benzyl L-glutamate)-block-hyaluronan polymersomes using a simple and reproducible nanoprecipitation method. The prepared DOC loaded polymersomes (PolyDOC) was stable either in solution or in a lyophilized form, and showed controlled release behaviour over several days. PolyDOC showed high in vitro toxicity after 24 h in MCF-7 and U87 cells compared to free DOC. Biodistribution data demonstrated that (99m)Tc labelled PolyDOC t(1/2) and MRT significantly increased compared to a DOC solution (DS). In addition, PolyDOC uptake in Ehrlich Ascites Tumor (EAT) tumor bearing mice was larger at each time point compared to DS, making such a polymer vesicle formulation an efficient drug nanocarrier for improved DOC cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Capsules
  • Cell Line, Tumor
  • Delayed-Action Preparations / chemistry*
  • Docetaxel
  • Female
  • Humans
  • Hyaluronic Acid / analogs & derivatives*
  • Hyaluronic Acid / chemistry
  • Mice
  • Mice, Inbred BALB C
  • Polyglutamic Acid / analogs & derivatives*
  • Polyglutamic Acid / chemistry
  • Rabbits
  • Taxoids / administration & dosage*
  • Taxoids / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Capsules
  • Delayed-Action Preparations
  • Taxoids
  • poly(gamma-benzyl glutamate)-b-hyaluronan
  • Docetaxel
  • Polyglutamic Acid
  • Hyaluronic Acid